PMID- 36669741
OWN - NLM
STAT- MEDLINE
DCOM- 20230222
LR  - 20230303
IS  - 2254-8874 (Electronic)
IS  - 2254-8874 (Linking)
VI  - 223
IP  - 2
DP  - 2023 Feb
TI  - Nonvalvular atrial fibrillation and retinal vein occlusion: The Valdecilla 
      Cohort.
PG  - 77-83
LID - S2254-8874(23)00009-7 [pii]
LID - 10.1016/j.rceng.2022.11.005 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Retinal vein occlusion (RVO) and nonvalvular atrial 
      fibrillation (NVAF) are associated with vascular risk factors (VRF) and aging. 
      The aim of this study is to analyze differences in the prevalence of VRF, 
      vascular events, glaucoma, and anticoagulant treatment in patients with NVAF and 
      RVO compared to a control group of the general population from the same 
      geographic area. METHODS: This is a prospective, single-center, case-control 
      study. All patients diagnosed with RVO from December 2008 to March 2020 as well 
      as a control group were included. Clinical, laboratory, electrocardiographic, and 
      carotid ultrasound variables were analyzed. RESULTS: A total of 386 patients with 
      RVO and 343 controls were studied. Patients with RVO and NVAF were older and more 
      of them had hypertension, a history of vascular events, and carotid atheromatosis 
      than subjects with RVO without NVAF. In patients with NVAF who were on 
      anticoagulants, those who had RVO differed from the controls with NVAF in that 
      they had a higher prevalence of glaucoma (32 vs. 5.3%; p<0.034), with no 
      significant differences regarding age, VRF, vascular events, or type of 
      anticoagulant therapy (acenocumarol or direct-acting oral anticoagulants). 
      CONCLUSIONS: Patients with RVO and NVAF were older and had a higher prevalence of 
      hypertension and carotid atheromatosis than subjects with RVO without NVAF. 
      Patients with NVAF and RVO had higher prevalence of glaucoma than subjects with 
      NVAF without RVO. In patients with NVAF, it is recommended to optimized VRF 
      treatment and glaucoma control to prevent the development of RVO.
CI  - Copyright (c) 2022 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina 
      Interna (SEMI). All rights reserved.
FAU - Gonzalez Bores, P
AU  - Gonzalez Bores P
AD  - Servicio de Medicina Interna, Hospital Universitario Marques de 
      Valdecilla-IDIVAL, Santander, Cantabria, Spain. Electronic address: 
      paula.gonzalezb@scsalud.es.
FAU - Napal Lecumberri, J J
AU  - Napal Lecumberri JJ
AD  - Servicio de Medicina Interna, Hospital Universitario Marques de 
      Valdecilla-IDIVAL, Santander, Cantabria, Spain.
FAU - de la Torre Hernandez, J M
AU  - de la Torre Hernandez JM
AD  - Servicio de Cardiologia, Hospital Universitario Marques de Valdecilla-IDIVAL, 
      Santander, Cantabria, Spain.
FAU - Gonzalez-Mesones Galan, B
AU  - Gonzalez-Mesones Galan B
AD  - Servicio de Hematologia, Hospital Universitario Marques de Valdecilla-IDIVAL, 
      Santander, Cantabria, Spain.
FAU - Hernandez Hernandez, J L
AU  - Hernandez Hernandez JL
AD  - Servicio de Medicina Interna, Hospital Universitario Marques de 
      Valdecilla-IDIVAL, Santander, Cantabria, Spain; Universidad de Cantabria, 
      Santander, Cantabria, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230118
PL  - Spain
TA  - Rev Clin Esp (Barc)
JT  - Revista clinica espanola
JID - 101632437
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - *Atrial Fibrillation/complications/epidemiology/drug therapy
MH  - Case-Control Studies
MH  - Prospective Studies
MH  - *Retinal Vein Occlusion/etiology/complications
MH  - Anticoagulants/therapeutic use
MH  - Risk Factors
MH  - *Hypertension/epidemiology
MH  - *Carotid Artery Diseases/chemically induced/complications/drug therapy
MH  - *Glaucoma/epidemiology/chemically induced/complications
OTO - NOTNLM
OT  - Anticoagulacion
OT  - Anticoagulation
OT  - Fibrilacion auricular no valvular
OT  - Glaucoma
OT  - Nonvalvular atrial fibrillation
OT  - Obstruccion venosa retiniana
OT  - Retinal vein occlusion
EDAT- 2023/01/21 06:00
MHDA- 2023/02/22 06:00
CRDT- 2023/01/20 19:26
PHST- 2022/03/21 00:00 [received]
PHST- 2022/11/15 00:00 [accepted]
PHST- 2023/01/21 06:00 [pubmed]
PHST- 2023/02/22 06:00 [medline]
PHST- 2023/01/20 19:26 [entrez]
AID - S2254-8874(23)00009-7 [pii]
AID - 10.1016/j.rceng.2022.11.005 [doi]
PST - ppublish
SO  - Rev Clin Esp (Barc). 2023 Feb;223(2):77-83. doi: 10.1016/j.rceng.2022.11.005. 
      Epub 2023 Jan 18.